Summary
Based on the high response rates seen among patients with colon cancer receiving high dose Melphalan with autologous marrow infusion, the Southwest Oncology Group conducted a Phase II trial of the compound at a conventional dose. The initial starting dose of 40 mg/m2 was reduced to 30 mg/m2 after severe myelotoxicity was encountered in the first five patients. Toxicity was primarily myeloid and was moderate to severe in most patients with one treatment related death. There were two complete and one partial response among 43 patients. Melphalan at 30 mg/m2 has little activity among patients with metastatic colorectal carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Leff RS, Thompson JM, Johnson DB, Mosley KR, Daly MB, Knight WA III, Ruxer RL, Messerschmidt GL: Phase II trial of high dose Melphalan and autologous bone marrow transplantation for metastatic colon carcinoma. J Clin Oncol 4 (11): 1586–1591, 1986
Knight WA III, Page CP, Kuhn JG, Clark GM, Bell BS, Newcomb TF: High dose Melphalan (L-PAM) with autologous bone marrow (ABM) infusion for Duke's D colorectal carcinoma. Proc Am Soc Clin Oncol 2: 118, 1983
Carter SK: Integration of chemotherapy into combined modality treatment of solid tumors-II, large bowel carcinoma. Cancer Treat Rev 1: 111–129, 1974
McElwain TJ, Hedley DW, Burton G, Clink HM, Gordon MY, Jarman M, Juttner CA, Millar JL, Milsted RAV, Prentice G, Smith IE, Spence D, Woods M: Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan. Br J Cancer 40: 72–80, 1979
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Knight, W.A., Goodman, P., Taylor, S.A. et al. Phase II trial of intravenous melphalan for metastatic colorectal carcinoma. Invest New Drugs 8 (Suppl 1), S87–S89 (1990). https://doi.org/10.1007/BF00171991
Issue Date:
DOI: https://doi.org/10.1007/BF00171991